Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Clinical and Radiologic Outcomes of the Surgical Treatment of Patellofemoral Instability in Children with Down Syndrome and Dislocated Patella: Case Series.

Bitar AC, D'Elia CO, Schor B, Bertoni J, Mustacchi Z, Grangeiro PM.

J Orthop Case Rep. 2018 Jul-Aug;8(4):61-65. doi: 10.13107/jocr.2250-0685.1162.

2.

Smartphone Apps Provide a Simple, Accurate Bedside Screening Tool for Orthostatic Tremor.

Bhatti D, Thompson R, Hellman A, Penke C, Bertoni JM, Torres-Russotto D.

Mov Disord Clin Pract. 2017 Oct 8;4(6):852-857. doi: 10.1002/mdc3.12547. eCollection 2017 Nov-Dec.

3.

Paradoxical worsening of parkinsonism upon neuroleptic withdrawal: More common than we think?

Florescu A, Whitney D, Bhatti D, Bertoni JM, Torres-Russotto D.

Parkinsonism Relat Disord. 2018 Jul;52:115-116. doi: 10.1016/j.parkreldis.2018.03.018. Epub 2018 Mar 20. No abstract available.

PMID:
29606607
4.

Comorbid Conditions in Parkinson's Disease: A Population-Based Study of Statewide Parkinson's Disease Registry.

Xu K, Alnaji N, Zhao J, Bertoni JM, Chen LW, Bhatti D, Qu M.

Neuroepidemiology. 2018;50(1-2):7-17. doi: 10.1159/000484410. Epub 2017 Dec 22.

PMID:
29275411
5.

Comprehensive, blinded assessment of balance in orthostatic tremor.

Bhatti D, Thompson R, Xia Y, Hellman A, Schmaderer L, Suing K, McKune J, Penke C, Iske R, Roeder BJ, Siu KC, Bertoni JM, Torres-Russotto D.

Parkinsonism Relat Disord. 2018 Feb;47:22-25. doi: 10.1016/j.parkreldis.2017.11.335. Epub 2017 Nov 16.

PMID:
29169787
6.

Nonconvulsive Status Epilepticus Resembling Clinical Absence with Atypical EEG Pattern.

Mysore CS, Murr N, Zabad R, Bertoni J.

Case Rep Neurol Med. 2017;2017:6987821. doi: 10.1155/2017/6987821. Epub 2017 Jan 19.

7.

A unique presentation of atypical SREDA pattern in a young healthy woman.

Murr N, Bertoni J.

Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):355-6. doi: 10.4103/0972-2327.157183.

8.

CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease.

Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, Ali HH, Standaert DG, Mosley RL, Gendelman HE.

J Neuroimmune Pharmacol. 2012 Dec;7(4):927-38. doi: 10.1007/s11481-012-9402-z. Epub 2012 Oct 11.

9.

Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.

Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr; North American Parkinson's and Melanoma Survey Investigators.

Arch Neurol. 2010 Mar;67(3):347-52. doi: 10.1001/archneurol.2010.1.

PMID:
20212233
10.

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

Elmer LW, Bertoni JM.

Expert Opin Pharmacother. 2008 Nov;9(16):2759-72. doi: 10.1517/14656566.9.16.2759 . Review.

PMID:
18937611
11.

Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.

Lew MF, Pahwa R, Leehey M, Bertoni J, Kricorian G; Zydis Selegiline Study Group.

Curr Med Res Opin. 2007 Apr;23(4):741-50.

PMID:
17407630
12.

Evaluation of Parkinson's disease in entrants on the Nebraska State Parkinson's Disease Registry.

Bertoni JM, Sprenkle PM, Strickland D, Noedel N.

Mov Disord. 2006 Oct;21(10):1623-6.

PMID:
16874754
13.

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.

Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; Zydis Selegiline Study Group.

Mov Disord. 2004 Apr;19(4):426-32.

PMID:
15077240
14.

Parkinson's prevalence estimated by a state registry.

Strickland D, Bertoni JM.

Mov Disord. 2004 Mar;19(3):318-23. Review.

PMID:
15022187
15.

Gabapentin for the treatment of tremor.

Faulkner MA, Bertoni JM, Lenz TL.

Ann Pharmacother. 2003 Feb;37(2):282-6. Review.

PMID:
12549962
16.

Prevention of auditory dysfunction in hypothyroid Tshr mutant mice by thyroxin treatment during development.

Sprenkle PM, McGee J, Bertoni JM, Walsh EJ.

J Assoc Res Otolaryngol. 2001 Dec;2(4):348-61.

17.

Development of auditory brainstem responses (ABRs) in Tshr mutant mice derived from euthyroid and hypothyroid dams.

Sprenkle PM, McGee J, Bertoni JM, Walsh EJ.

J Assoc Res Otolaryngol. 2001 Dec;2(4):330-47.

18.

Consequences of hypothyroidism on auditory system function in Tshr mutant (hyt) mice.

Sprenkle PM, McGee J, Bertoni JM, Walsh EJ.

J Assoc Res Otolaryngol. 2001 Dec;2(4):312-29.

19.

Long-term Medical Treatment for Parkinson's Disease.

Bertoni JM, Prendes JL, Sprenkle P.

Curr Treat Options Neurol. 2001 Nov;3(6):495-506.

PMID:
11581526
20.

Hyperacute ischemic stroke missed by diffusion-weighted imaging.

Lefkowitz D, LaBenz M, Nudo SR, Steg RE, Bertoni JM.

AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1871-5.

21.

[Women's labor force in Chile: figures and characteristics].

Bertoni JS.

Rev Lat Am Enfermagem. 1998 Dec;6(5):53-8. Portuguese.

PMID:
9934244
22.

Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group.

Sethi KD, O'Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA.

Arch Neurol. 1998 Sep;55(9):1211-6.

PMID:
9740115
23.

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.

Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF.

Neurology. 1997 Aug;49(2):393-9. Erratum in: Neurology 1997 Nov;49(5):1484.

PMID:
9270567
24.

Descriptive epidemiology of Parkinson's disease through proxy measures.

Strickland D, Bertoni JM, Pfeiffer RF.

Can J Neurol Sci. 1996 Nov;23(4):279-84.

PMID:
8951206
25.

Effects of in vitro ethanol on the brain cation pump in alcoholics and controls.

Bertoni JM, Sprenkle PM.

Biochem Pharmacol. 1994 Jul 19;48(2):435-7.

PMID:
8053941
26.

[Effects of personalized counseling in the reduction of pressure levels in patients with severe essential hypertension. WHO 1].

Bertoni JS, Klijn TP, Carreño CG, Bugueño HD.

Rev Lat Am Enfermagem. 1994 Jan;2(1):19-30. Portuguese.

PMID:
7551066
27.

Familial Creutzfeldt-Jakob disease (codon 200 mutation) with supranuclear palsy.

Bertoni JM, Brown P, Goldfarb LG, Rubenstein R, Gajdusek DC.

JAMA. 1992 Nov 4;268(17):2413-5.

PMID:
1404799
28.

Effects of short photoperiod on ATPase activities in the testis of the immature Siberian hamster.

Bertoni JM, Sprenkle PM, Hanifin JP, Stetson MH, Brainard GC.

Biol Reprod. 1992 Oct;47(4):509-13.

PMID:
1327208
29.

Application of positron emission tomography to neurological oncology.

Chin HW, Fruin AH, Bertoni JM, Frick MP, Shiue CY, McClellan G, Lefkowitz D, Taylon C, Boman BM.

Nebr Med J. 1991 Mar;76(3):70-3.

PMID:
1851543
30.

Low level lead inhibits the human brain cation pump.

Bertoni JM, Sprenkle PM.

Life Sci. 1991;48(22):2149-56.

PMID:
1851920
31.

Physiological doses of epinephrine in the human: chronotropic but not hyperglycemic or catecholaminotropic.

Epple A, Bertoni JM, Hathaway CB.

J Exp Zool. 1989 Apr;250(1):67-72.

PMID:
2723611
32.

Ganglion cysts and carpal tunnel syndrome.

Kerrigan JJ, Bertoni JM, Jaeger SH.

J Hand Surg Am. 1988 Sep;13(5):763-5.

PMID:
3241055
33.

Overview of gait and movement disorders in the elderly.

Bertoni JM.

Compr Ther. 1988 Jul;14(7):46-50. Review. No abstract available.

PMID:
3060305
34.
35.

Lead acutely reduces glucose utilization in the rat brain especially in higher auditory centers.

Bertoni JM, Sprenkle PM.

Neurotoxicology. 1988 Summer;9(2):235-42.

PMID:
3205433
36.

Inhibitors of cation pump enzyme equally present in normal and ischemic gerbil brain.

Bertoni JM, Sprenkle PM.

Life Sci. 1988;42(20):1955-62.

PMID:
2452947
38.

Diurnal variation of cation pump enzyme activity in pineal and seven other rat brain regions.

Bertoni JM, Sprenkle PM, Rollag MD, Binkley S, Brainard GC.

J Pineal Res. 1987;4(1):33-43.

PMID:
3031264
39.

Moxalactam myoclonus, seizures, and encephalopathy.

Cho I, Bertoni JM, Hopkins L.

Drug Intell Clin Pharm. 1986 Mar;20(3):223-4.

PMID:
3956381
40.

Small bowel resection with vitamin E deficiency and progressive spinocerebellar syndrome.

Bertoni JM, Abraham FA, Falls HF, Itabashi HH.

Neurology. 1984 Aug;34(8):1046-52.

PMID:
6540384
41.

Competitive inhibition of human brain hexokinase by metrizamide and related compounds.

Bertoni JM, Weintraub ST.

J Neurochem. 1984 Feb;42(2):513-8.

PMID:
6693884
42.

Supranuclear gaze palsy in familial Creutzfeldt-Jakob disease.

Bertoni JM, Label LS, Sackelleres JC, Hicks SP.

Arch Neurol. 1983 Oct;40(10):618-22.

PMID:
6351815
43.

Urine and plasma free phenytoin concentration correlation.

Casto DT, Ludden TM, Bertoni JM, Littlefield LC, Sagraves RA, Mackey RW.

Clin Pharmacol Ther. 1982 Nov;32(5):628-34.

PMID:
7128003
44.

Aseptic meningitis complicating metrizamide myelography.

Baker FJ, Gossen G, Bertoni JM.

AJNR Am J Neuroradiol. 1982 Nov-Dec;3(6):662-3. No abstract available.

PMID:
6816043
45.

Metrizamide inhibits human brain hexokinase.

Bertoni JM.

Neurology. 1982 Aug;32(8):884-7.

PMID:
7201585
46.
47.

Competitive inhibition of brain hexokinase by metrizamide.

Bertoni JM, Steinman CG.

Neurology. 1982 Mar;32(3):320-3.

PMID:
7199650
48.
49.

Studies on the mechanism of toxicity of metrizamide-competitive inhibition of yeast hexokinase.

Bertoni JM, Alexander GM.

Biochem Pharmacol. 1981 May 15;30(10):1137-8. No abstract available.

PMID:
7020703
50.

Supplemental Content

Loading ...
Support Center